Precision Biosciences expects to report approximately $108.5 million in cash as of December 31, 2024, and anticipates its cash runway will extend into the second half of 2026, supporting two Phase 1 programs. The company also received a $2.5 million payment from TG Therapeutics and issued shares as part of a licensing agreement.